首页> 外文OA文献 >SAT0155 THE PRESENCE OF ANTI-NUCLEAR ANTIBODIES BEFORE ANTI-TNF THERAPY IS A RISK FACTOR FOR THE APPEARANCE OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS

【2h】

SAT0155 THE PRESENCE OF ANTI-NUCLEAR ANTIBODIES BEFORE ANTI-TNF THERAPY IS A RISK FACTOR FOR THE APPEARANCE OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS

机译：SAT0155抗TNF治疗前的抗核抗体存在是类风湿性关节炎患者抗药抗体外观的危险因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Shunichi Kumagai; Ayano Mori; Toshiharu Saito; Miho Takahashi; Katsuhiko Yoneda; Yasuhiro Noda; Soushi Takahashi; Miwa Nishida; Saori Hatachi; Goh Tsuji;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy [J] . Moses Jonathan, Lambert-Jenkins Kristin, Momotaz Hasina, European journal of gastroenterology and hepatology . 2019,第10期

机译：用于抗TNF治疗治疗的儿科炎症性肠病患者的抗药性抗体存在的抗体检测和相关因素的时间
2. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial [J] . Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, Arthritis research & therapy. . 2019,第1期

机译：抗风湿性关节炎（RA）患者对甲氨蝶呤背景疗法的反应不足，对抗氨甲蝶呤疗法的反应不足或不耐受的类风湿性关节炎（RA）患者抗粒细胞巨噬细胞集落刺激因子（GM-CSF）配体的人类单克隆抗体那米单抗的疗效和安全性-TNF（肿瘤坏死因子）生物疗法：一项随机对照试验
3. Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets [J] . Davis Laurie S., Reimold Andreas M. Experimental and therapeutic medicine . 2017,第5aPta2期

机译：抗肿瘤坏死因子治疗前后类风湿性关节炎患者的白细胞转录分析：抗核抗体阳性和负子集的比较
4. Development of a Protease-Activated Antibody That Reduces the Side-Effects of Rheumatoid Arthritis (RA) Therapy [C] . Tian-Lu Cheng, Chih-Hung Chuang Protein Engineering Summit. . 2018

机译：蛋白酶活化抗体的研制降低了类风湿性关节炎（RA）治疗的副作用
5. Monoclonal antibody therapy of rheumatoid arthritis. [D] . Hammaker, Deepa Rajan. 1999

机译：类风湿关节炎的单克隆抗体治疗。
6. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis [O] . Ayano Mori, Toshiharu Saito, Miho Takahashi, 2020

机译：抗核抗体存在是类风湿性关节炎患者英夫利昔单抗或患者的抗药物抗体外观的危险因素
7. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial [O] . Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, 2019

机译：芽孢杆菌的疗效和安全性，一种针对类风湿性关节炎（RA）患者的粒细胞 - 巨噬细胞菌落刺激因子（GM-CSF）配体的人单克隆抗体，其对背景甲氨蝶呤治疗的反应不足或反应不足或对抗的不容忍-TNF（肿瘤坏死因子）生物疗法：随机，受控试验

SAT0155 THE PRESENCE OF ANTI-NUCLEAR ANTIBODIES BEFORE ANTI-TNF THERAPY IS A RISK FACTOR FOR THE APPEARANCE OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS

著录项

引文网络

相似文献

相关主题

期刊订阅